Nurexone Biologic Inc
F:J90
Income Statement
Earnings Waterfall
Nurexone Biologic Inc
Income Statement
Nurexone Biologic Inc
| Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||
| Operating Expenses |
(0)
|
(2)
|
(4)
|
(5)
|
(6)
|
(6)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(6)
|
(6)
|
(6)
|
|
| Selling, General & Administrative |
(0)
|
(2)
|
(3)
|
(4)
|
(4)
|
(3)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
|
| Research & Development |
0
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(0)
N/A
|
(2)
-1 699%
|
(4)
-62%
|
(5)
-26%
|
(6)
-16%
|
(6)
-10%
|
(4)
+41%
|
(4)
-5%
|
(4)
+3%
|
(4)
-6%
|
(4)
-7%
|
(4)
-3%
|
(5)
-18%
|
(6)
-16%
|
(6)
-9%
|
(6)
-3%
|
|
| Pre-Tax Income | |||||||||||||||||
| Interest Income Expense |
0
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Non-Reccuring Items |
0
|
0
|
(2)
|
(2)
|
(2)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(0)
N/A
|
(2)
-1 766%
|
(6)
-155%
|
(7)
-17%
|
(8)
-13%
|
(7)
+20%
|
(4)
+42%
|
(4)
-3%
|
(4)
+7%
|
(4)
-6%
|
(4)
-7%
|
(4)
-2%
|
(5)
-19%
|
(6)
-15%
|
(6)
-9%
|
(7)
-3%
|
|
| Net Income | |||||||||||||||||
| Income from Continuing Operations |
(0)
|
(2)
|
(6)
|
(7)
|
(8)
|
(7)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(4)
|
(5)
|
(6)
|
(6)
|
(7)
|
|
| Net Income (Common) |
(0)
N/A
|
(2)
-1 766%
|
(6)
-155%
|
(7)
-17%
|
(8)
-13%
|
(7)
+20%
|
(4)
+42%
|
(4)
-3%
|
(4)
+7%
|
(4)
-6%
|
(4)
-7%
|
(4)
-2%
|
(5)
-19%
|
(6)
-15%
|
(6)
-9%
|
(7)
-3%
|
|
| EPS (Diluted) |
-0.05
N/A
|
-0.07
-40%
|
-0.18
-157%
|
-0.2
-11%
|
-0.22
-10%
|
-0.15
+32%
|
-0.09
+40%
|
-0.09
N/A
|
-0.08
+11%
|
-0.08
N/A
|
-0.08
N/A
|
-0.07
+12%
|
-0.08
-14%
|
-0.09
-12%
|
-0.09
N/A
|
-0.09
N/A
|
|